Navigation Links
Amarin Secures Global Intellectual Property Rights for Lipid Programs
Date:3/3/2008

ection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks relating to the Company's ability to maintain its Nasdaq listing; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International and US generally accepted accounting principles; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the SEC on March 5, 2007, Amarin's statutory annual report for the year ended 31 December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007, Amarin's Report of Foreign Issuer (Updated and Additional Risk
'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Appoints Dr. William Mason as Lead Independent Director
2. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
3. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
4. Amarin Signs Agreement to Acquire Ester Neurosciences
5. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
6. Amarin Announces Initiation of Cardiovascular Development Strategy
7. Amarin to Present at 4th Annual Bio Investor Forum
8. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
9. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... SOMERSET, N.J., June 9 Alfacell Corporation,(Nasdaq: ACEL ... quarter,of fiscal 2008., The company recorded a net ... diluted common share, for the third fiscal quarter ended,April ... million, or $0.04,per basic and diluted common share, for ...
... Limited (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical ... lots of the ADHD patch DAYTRANA (lots,2750211 and ... DAYTRANA,patches do not meet their release liner removal ... have difficulties removing the,liners. This voluntary recall is ...
... 9 Amira Pharmaceuticals, a small,molecule pharmaceutical company ... treat inflammatory diseases, announced the hiring of Michael,V. ... Swanson has over 30 years of experience in ... in life sciences and specialty,pharmaceutical companies. Prior to ...
Cached Biology Technology:Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 2Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 3Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 4Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 5Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 6Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 2Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 3Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 4Amira Pharmaceuticals Hires Industry Veteran for CFO Position 2
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University is proving its potential to impact global health. ... journal PLoS ONE , Rice alumnus Andrew Miller ... which costs $240, stacks up nicely against devices that ... of tuberculosis. Miller and colleagues at The Methodist ...
... not recognized as an animal until the 19th century, is ... have their genome sequenced. In a paper appearing in ... a team of researchers led by Daniel Rokhsar of the ... Genome Institute (JGI), report the draft genome sequence of the ...
... How well do you understand life in your own backyard? Cities ... aren,t visitors; they are an integral component, like trees in a ... the Earth,s people live in cities and the amount of paved ... Ohio, shouldn,t our sciences thrive in the city? Urban Ecosystem ...
Cached Biology News:Compact microscope a marvel 2Compact microscope a marvel 3Genome of ancient sponge reveals origins of first animals, cancer 2Genome of ancient sponge reveals origins of first animals, cancer 3Genome of ancient sponge reveals origins of first animals, cancer 4The real urban jungle 2
...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
Biology Products: